HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet

— First randomized Phase III trial confirming the efficacy of MET inhibition in patients with advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment — — Savolitinib and osimertinib combination approved in China in June 2025 — HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today highlights that results from the SACHI Phase III trial were published in The Lancet. SACHI is a Pha ...